2020
Response to Letter to the Editor: “Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin”
Wilson JR, Shuey MM, Brown NJ, Devin JK. Response to Letter to the Editor: “Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin”. Journal Of The Endocrine Society 2020, 4: bvaa006. PMID: 32133430, PMCID: PMC7049288, DOI: 10.1210/jendso/bvaa006.Peer-Reviewed Original Research
2017
Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin
Wilson JR, Shuey MM, Brown NJ, Devin JK. Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin. Journal Of The Endocrine Society 2017, 1: 1168-1178. PMID: 29264572, PMCID: PMC5686657, DOI: 10.1210/js.2017-00312.Peer-Reviewed Original ResearchDPP4 activityHealthy controlsSitagliptin doseSystolic blood pressurePeptidase-4 inhibitorsType 2 diabetesDipeptidyl peptidase-4Blood pressureCrossover fashionMetabolic syndromeCrossover studyMultivariable analysisDPP4 inhibitionDPP4 inhibitorsHypertensionPlaceboPeptidase-4High dosesSitagliptinT2DMDecreased inhibitionPatientsLaboratory dataInfluences responseDiabetes